Compare ADMA Biologics Inc (ADMA) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Wheaton Precious Metals Corp — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Wheaton Precious Metals Corp trades at $107.75 (market cap $50.76B). The key difference: Wheaton Precious Metals Corp is far larger — about 23.8× ADMA Biologics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.7% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WPM | |
|---|---|---|
Market Cap | $2.13B | $50.76B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $165.72 |
52-Week Low | $7.60 | $86.72 |
Enterprise Value | $2.20B | $48.61B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Wheaton Precious Metals (WPM) trades at $111.89, down 3.32% recently amid broader precious metals volatility. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, supported by three consecutive quarterly EPS beats. Technical indicators signal bearish momentum with key support at $109, while analyst consensus remains strongly bullish with an $169 price target representing 51% upside potential from current levels.
WPM presents a compelling growth story with exceptional profitability margins (65.55% net income margin) and projected 2026 revenue growth to $2.7B. Primary risks include precious metal price volatility and geopolitical tensions affecting mining operations. The 80% buy rating from analysts suggests significant upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
